NCT04582409View on ClinicalTrials.gov

A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation

PHASE2TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

November 30, 2020

Primary Completion Date

July 11, 2022

Study Completion Date

July 11, 2022

Conditions
Atrial Fibrillation
Interventions
DRUG

HSY244

HSY244 concentrate solution for injection via intravenous infusion

OTHER

Placebo

Placebo concentrate solution for injection via intravenous infusion

Trial Locations (4)

32545

Novartis Investigative Site, Bad Oeynhausen

48912

Novartis Investigative Site, Lansing

60590

Novartis Investigative Site, Frankfurt

02215

Novartis Investigative Site, Boston

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY